Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20656759 | 0.84 | LMNA (0.43) | LMNA | |
| SCHEMBL2275801 | 0.82 | LMNA (0.63) | LMNATHRB | |
| Alcohol SCHEMBL1490179 | 0.81 | LMNA (0.80) | LMNATHRB | |
| SCHEMBL9295759 | 0.79 | LMNA (0.67) | LMNATHRB | |
| Ethylene Glycol SCHEMBL356222 | 0.78 | LMNA (0.75) | LMNATHRB | |
| SCHEMBL7042976 | 0.78 | LMNA (0.57) | LMNATHRB | |
| Methyl Alcohol SCHEMBL5434659 | 0.78 | LMNA (0.86) | LMNATHRB | |
| SCHEMBL2094168 | 0.78 | LMNA (1.00) | LMNATHRB | |
| SCHEMBL9459 | 0.78 | — | — | |
| SCHEMBL11288604 | 0.77 | LMNA (0.63) | LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112537998-B | Process for producing neopentyl glycol by continuous catalytic hydrogenation | 上海翼湍科技有限责任公司 | 2022-12-23 | — | — | CN | claimed |
| CN-112537998-A | Process for producing neopentyl glycol by continuous catalytic hydrogenation | 上海翼湍科技有限责任公司 | 2021-03-23 | — | — | CN | claimed |
| CN-103351277-B | Neopentyl glycol preparation method | WANHUA CHEMICAL GROUP CO LTD | 2014-12-31 | — | — | CN | claimed |
| CN-103351277-A | Neopentyl glycol preparation method | WANHUA CHEMICAL GROUP CO LTD | 2013-10-16 | — | — | CN | claimed |
| CN-118239948-A | Solid forms and methods of making fused tricyclic compounds, including methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-117946107-A | Solid forms and methods of making fused tricyclic compounds, including methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-4295845-A2 | SOLID FORMS OF THE TARTRATE SALT OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL, PROCESS FOR THEIR PREPARATION AND METHODS OF THEIR USE IN TREATING CANCERS | F. Hoffmann-La Roche AG (CH) | 2023-12-27 | — | — | EP | disclosed |
| US-11780834-B2 | Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3- yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use | GENENTECH, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| EP-3810283-B1 | SOLID FORMS OF THE TARTRATE SALT OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL, PROCESS FOR THEIR PREPARATION AND METHODS OF THEIR USE IN TREATING CANCERS | HOFFMANN LA ROCHE (CH) | 2023-06-14 | — | — | EP | disclosed |
| CN-112537998-B | Process for producing neopentyl glycol by continuous catalytic hydrogenation | 上海翼湍科技有限责任公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-111822050-B | Carbonylation reaction catalyst composition and method for preparing neopentyl glycol | 万华化学集团股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-112755932-A | System for continuously synthesizing hydroxypivalaldehyde | 中国五环工程有限公司 | 2021-05-07 | — | — | CN | disclosed |
| US-20030092775-A1 | Process for the preparation of meso-zeaxanthin | BASF AKTIENGESELLSCHAFT (DE) | 2003-05-15 | — | — | US | disclosed |
| CN-1406933-A | Meso cryptoxanthine preparation | BASF AG (DE) | 2003-04-02 | — | — | CN | disclosed |
| CN-1156440-A | Method for producing acyloins | BASF AG (DE) | 1997-08-06 | — | — | CN | disclosed |
| US-5276209-A | Preparation of polyenes | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-04 | — | — | US | disclosed |
| US-5126500-A | PREPARATION OF RETINYL GLYCOSIDES AND INTERMEDIATES THEREFOR | BASF AKTIENGESELLSCHAFT (DE) | 1992-06-30 | — | — | US | disclosed |
| US-4851425-A | Cyclopentapyrazole and tetrahydroindazole compounds and their use as anti-inflammatory and anti-allergic agents | THE UPJOHN COMPANY (US) | 1989-07-25 | — | — | US | disclosed |
| WO-1986007357-A3 | CYCLOPENTAPYRAZOLE AND TETRAHYDROINDAZOLE COMPOUNDS | THE UPJOHN COMPANY (US) | 1987-04-23 | — | — | WO | disclosed |
| US-3966751-A | Oxazolidines of 4-oxo-tricyclo[5.1.02.5 ]octan-8-endo-carboxaldehyde, neopentyl glycol acetal | THE UPJOHN COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780834-B2 | Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3- yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use | TP53, DPYD, FLI1 | LMNA 2912/4885THRB 1182/4885 |
| US-20030092775-A1 | Process for the preparation of meso-zeaxanthin | CYP8B1, MTX1, CYP11A1 | LMNA 1136/4885THRB 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.